Seamless Therapeutics' platform has succeeded in reprogramming site specific recombinases to any given target sequence which can be a disease target, for example, and make a range of specific changes including inversion, excision, exchange, and insertion from small to larger DNA fragments. Recombinases are a class of enzymes that have been widely used in scientific research for decades to precisely modify the genome of model organisms but until now have been limited in their applicability as a therapeutic due to their limited programmability to act on new target sites. The company is applying its proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.
Location: Germany, Saxony, Dresden
Total raised: $12.5M
Investors 1
| Date | Name | Website |
| - | Forbion | forbion.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.03.2023 | Seed | $12.5M | Forbion |
Mentions in press and media 3
| Date | Title | Description |
| 23.04.2024 | Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform | DRESDEN, Germany & LEXINGTON, Mass.--(BUSINESS WIRE)-- Seamless Therapeutics today announced the appointments of Albert Seymour, Ph.D., as its new President and Chief Executive Officer and Adam Rosenberg as Independent Chairman of the c... |
| 16.03.2023 | Seamless Therapeutics Raises $12.5M in Seed Financing | Seamless Therapeutics, a Dresden, Germany-based biotechnology company providing a recombinase platform, raised $12.5M in Seed funding. The round was led by Wellington Partners and Forbion, with non-dilutive funding from BMBF GO-Bio. Represe... |
| - | Seamless Therapeutics | “Seamless Therapeutics – Overcoming the boundaries of gene editing by unlocking the full potential of recombinases.” |